- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02409108
Perfusion-Induced Hyperthermia for Metastatic Carcinoma
An Early Feasibility Study of Perfusion-Induced Hyperthermia for Metastatic Non-Small Cell Lung Carcinoma and All Relapsed Malignancies, for Which Curative Therapy is Not Possible
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky, Markey Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have histologically or cytologically confirmed diagnosis of Stage IIIB or Stage IV of non-small cell lung cancer and have received at least two lines of FDA-approved or National Comprehensive Cancer Network (NCCN) accepted systemic therapy and progressed through, or not tolerated, such therapy.
- Subjects whose tumors harbor an exon 19 deletion or exon 21L858R EGFR mutation must have progressed on or had intolerance to EGFR tyrosine kinase inhibitor.
- Subjects whose tumors harbor an AKL translocation must have progressed on or had intolerance to crizotinib (or any FDA approved ALK inhibitor).
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
Must have undergone at least 2 prior regimens for treatment of recurrent or metastatic disease
- Life expectancy of greater than 3 months.
- Age ≥22 years.
- There is no restriction on the number of prior therapies allowed for this disease and prior radiation and chemotherapy is allowed, provided the subject has recovered from all grade 2 or greater toxicity prior to enrollment.
- Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provide written informed consent prior to the procedure
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, or monoclonal antibodies such as bevacizumab, cetuximab or panitumumab) prior to entering the study or those who have not recovered to < grade 2 adverse events due to agents administered more than 4 weeks earlier.
- Patients with stroke or TIA within 90 days prior to enrollment; or peripheral vascular disease requiring intervention within the 90 days prior to enrollment; or any known hemodynamically significant lesion or embolic plaque.
Patients must have normal organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- total Bilirubin, AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- glomerular filtration rate (GFR)> 60 as defined by the Modification of Diet in Renal Disease (MDRD) formula
- Thromboplastin Time (PTT) < 35 sec)
- Patients with uncontrolled seizure disorder, spinal cord compression or carcinomatous meningitis.
- Patients with a mental disorder, psychiatric illness/social or concussion which would inhibit their ability to provide informed consent or prevent compliance with follow-up.
- Patients with high risk of cardiovascular event such as severe uncontrolled hypertension (>170/110 systemic blood pressure on therapy), or pulmonary hypertension (greater than .5 systolic blood pressure
- ST elevation myocardial infarction within 30 days prior to enrollment; unstable angina or significant, untreated arrhythmias within 30 days prior to enrollment.
- Patients with moderate to severe heart failure, New York Heart Association (NYHA) class III or IV, liver dysfunction with total bilirubin >2. 5 upper limit of normal, or serum creatinine >2.5 mg/dL or any form of dialysis; within 30 days prior to enrollment.
- Patients with a major surgical procedure or other investigational agents within 30 days before study enrollment.
- Patients with known, untreated or progressive brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Pregnant women are excluded from this study
- Patients with documented contraindication to anticoagulation therapy such as heparin induced thrombocytopenia or a documented coagulopathy or hematologic disorder that would contraindicated undergoing treatment and use of the associated anticoagulant agents required during treatment.
- Patients with documented active bacterial, viral or fungal infection, untreated systematic peptic ulcer disease, uncontrolled diabetes mellitus or serious concurrent medical disease that could limit survival to less than 3 months.
- HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for harm when exposed to hyperthermia, as well as negative interactions of these medications with hyperthermia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exatherm-TBH system
One treatment of Total Body Hyperthermia
|
One treatment of Total Body Hyperthermia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by adverse events
Time Frame: Up to 12 weeks after treatment
|
Incidence of adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0.
Adverse event data and corresponding toxicity grades during treatment will be summarized in the form of tables.
Incidence tables will be generated to summarize incidence of patients reporting at least one episode of each specific adverse event, incidence of adverse events causing withdrawal and incidence of serious adverse event.
The total number of episodes for each event reported (Frequency Table), the severity and attribution to study therapy of each episode reported (Severity Table and Attribution Table) will also be displayed.
Safety data will be summarized for the overall treated group and the overall concurrent control group.
Reversibility of the adverse events and toxicities will also be summarized.
|
Up to 12 weeks after treatment
|
Exatherm-TBH device functionality
Time Frame: Time frame: day 1
|
Device functionality will be documented and summarized using descriptive statistics and presented in the form of tables
|
Time frame: day 1
|
Safety as measured by serious adverse events
Time Frame: Up to 12 weeks after treatment
|
Incidence of serious adverse events associated with hyperthermic treatment as graded by the NCI CTCAE v. 4.0.
Summarized in the form of tables.
Listings of adverse events by patients will include the time to onset, the duration of each event, the severity of each event, and the relationship of the event to study therapy, whether it was a serious event, and whether it caused withdrawal.
|
Up to 12 weeks after treatment
|
Quality of Life
Time Frame: Baseline and up to 1 year after treatment
|
Assess changes in quality of life as documented by the EQ-DL-3L.
QOL and neurocognitive testing will be summarized using descriptive statistics including mean, median and variation levels of QOL score
|
Baseline and up to 1 year after treatment
|
Complication rates associated with hyperthermic treatment
Time Frame: Up to 12 weeks post-treatment
|
Complication rates will be documented and summarized using descriptive statistics and presented in the form of tables
|
Up to 12 weeks post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: Up to 12 weeks after treatment
|
Assess clinical benefit rate as documented by CR+PR+SD.
|
Up to 12 weeks after treatment
|
Time to treatment failure
Time Frame: Up to 12 weeks after treatment
|
Documentation of disease progression presented with Kaplan Meier curve.
|
Up to 12 weeks after treatment
|
Progression free survival
Time Frame: Baseline up to 1 year
|
Progression free survival following hyperthermic therapy presented with Kaplan Meier curve
|
Baseline up to 1 year
|
Death
Time Frame: Baseline up to 1 year
|
Documentation of time of death presented with Kaplan Meier curve
|
Baseline up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Kiev, MD, Lucille P. Markey Cancer Center at University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Wounds and Injuries
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Body Temperature Changes
- Heat Stress Disorders
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Hyperthermia
Other Study ID Numbers
- MCC-14-0929-F3R
- 2014-089 (Other Identifier: University of Kentucky)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on Exatherm-TBH system
-
University of Alabama, TuscaloosaUnknown
-
AstraZenecaRecruitingAsthmaUnited States, Canada, Italy, Japan, Vietnam, Spain, Germany, Malaysia
-
Pearl Therapeutics, Inc.Completed
-
Pearl Therapeutics, Inc.CompletedChronic Obstructive Pulmonary DisorderUnited States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
-
AstraZenecaCompleted
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada